Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of “Buy” by Analysts

Shares of Xencor, Inc. (NASDAQ:XNCR) have been assigned a consensus recommendation of “Buy” from the nine brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $34.78.

A number of equities analysts recently weighed in on XNCR shares. Royal Bank of Canada lifted their target price on shares of Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a research note on Thursday, September 26th. Wedbush reissued an “outperform” rating and set a $34.00 target price on shares of Xencor in a research note on Monday, September 9th. JPMorgan Chase & Co. lowered their target price on shares of Xencor from $30.00 to $27.00 and set an “overweight” rating for the company in a research note on Wednesday, July 31st. Finally, BMO Capital Markets reissued an “outperform” rating and set a $32.00 target price on shares of Xencor in a research note on Tuesday, August 6th.

Xencor Price Performance

XNCR stock opened at $21.16 on Friday. The company has a fifty day moving average price of $19.51 and a 200-day moving average price of $20.11. The company has a market capitalization of $1.30 billion, a P/E ratio of -9.66 and a beta of 0.67. Xencor has a 52-week low of $15.31 and a 52-week high of $26.84. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.92 and a current ratio of 6.92.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.25). The business had revenue of $16.96 million for the quarter, compared to the consensus estimate of $21.13 million. Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%. Xencor’s revenue was down 62.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.37) EPS. As a group, equities analysts expect that Xencor will post -4.11 EPS for the current year.

Institutional Investors Weigh In On Xencor

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in Xencor by 1.7% in the fourth quarter. Vanguard Group Inc. now owns 6,767,249 shares of the biopharmaceutical company’s stock valued at $143,669,000 after purchasing an additional 115,886 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in Xencor in the first quarter valued at $4,608,000. Entropy Technologies LP acquired a new position in shares of Xencor during the first quarter valued at about $573,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Xencor by 9.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,819,656 shares of the biopharmaceutical company’s stock valued at $84,530,000 after buying an additional 335,881 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in shares of Xencor by 43.1% during the first quarter. Russell Investments Group Ltd. now owns 224,140 shares of the biopharmaceutical company’s stock valued at $4,960,000 after buying an additional 67,522 shares during the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.